



T: 212.735.3245
lea.nehmeh@skadden.com

Education

J.D., Duke Law School, 2017

Law Degree, Université Saint-Joseph,
2011

Bar Admissions

New York

Languages

Arabic

French

Lea Nehmeh regularly counsels public and private clients, financial institutions, private equity sponsors, portfolio companies and special committees on a variety of U.S. and cross-border corporate matters. Ms. Nehmeh has represented a diverse range of clients in a variety of industries in mergers, acquisitions, dispositions, auctions, carve-outs, investments, joint ventures, restructurings and other corporate and commercial transactions.

Selected representations include:

- A. Schulman, Inc. in its acquisition by LyondellBasell N.V.
- BlackRock, Inc. in its \$12 billion acquisition of HPS Investment Partners
- Capgemini in its \$3.3 billion acquisition of WNS (Holding) Limited
- CC Capital in its \$2.2 billion acquisition of Insignia Financial Ltd
- CPI International, Inc. in its acquisition of L3 ESSCO, Inc. from an affiliate of L3Harris Technologies, Inc.
- Criteo Corp. in its acquisition of Gradient Technologies, Inc.
- Danaher Corporation in its acquisition of Sedaru, Inc.
- Dentsply Sirona Inc. in connection with various matters, including its acquisitions of Byte and Propel Orthodontics
- Fortress Investment Group LLC in:
 - the sale of TRAC Intermodal Holding Corp. to Stonepeak Infrastructure Partners
 - FTAI Aviation Ltd.'s internalization of management
- Hg in numerous transactions and corporate matters, including its:
 - acquisition of Optro (f/k/a AuditBoard)
 - investment in Revalize, Inc.
 - acquisition of GTreasury
 - investment in Benevity, Inc.
- Mars, Incorporated in its acquisition of NomNomNow Inc.
- Mubadala Investment Company in its:
 - significant reinvestment in PCI Pharma Services alongside Bain Capital and existing investor Kohlberg
 - co-investment with Bain Capital in Service Logic
- Nasdaq in its sale of Solovis to Insight Partners
- Revance Therapeutics in its merger with Crown Laboratories
- Rithm Capital Corp. in its acquisition of Crestline Management, L.P
- SiteOne Therapeutics in its acquisition by Eli Lilly
- Valaris Limited in its pending all-stock transaction with Transocean Ltd. to create a \$17 billion combined company
- Veritas Capital and certain of its portfolio companies in various transactions and corporate matters, including the acquisition, together with Evergreen Coast Capital Corporation, of Cubic Corporation